Clinical Trials Browser

Phase 1/2 × NIH × Lenalidomide × Clear all

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1/2 Active not recruiting

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT01057121 2022-02-08

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Phase 1/2 Completed

38 enrolled 11 charts

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi, HIV Infections

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Phase 1/2 Completed

127 enrolled 18 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT01076543 2019-10-16

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Phase 1/2 Completed

110 enrolled 17 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone